文献速递间质性肺疾病

加巴喷丁治疗特发性肺纤维化咳嗽的随机双盲安慰剂对照试验

Efficacy and Safety of Gabapentin for Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized, Double-Masked, Placebo-Controlled Clinical Trial.
PubMed 文献 · Chest · 2026-08-29

在特发性肺纤维化(IPF)慢性咳嗽患者中开展的随机双盲安慰剂对照试验显示,加巴喷丁治疗12周后咳嗽缓解率(总咳嗽症状评分较基线下降≥50%的比例)为73.5%,显著高于安慰剂的26.5%,安慰剂校正绝对差47.1个百分点(95%CI 26.1-68.0,P<.001);加巴喷丁组不良事件发生率32.4%,以嗜睡、乏力、头晕最常见。

要点

  • 加巴喷丁治疗IPF相关咳嗽12周,咳嗽缓解率显著优于安慰剂。
  • 加巴喷丁组不良事件32.4%,常见嗜睡、乏力、头晕,安全性可接受。
  • 结果支持加巴喷丁作为IPF相关咳嗽的潜在治疗选择。

核心结论

  • 加巴喷丁治疗IPF相关咳嗽显示显著疗效且安全性可接受,支持其作为潜在治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,在同济大学附属同济医院开展,68例IPF伴慢性咳嗽患者随机1:1接受加巴喷丁或安慰剂。
  • 加巴喷丁在12周治疗期内滴定至最大900 mg/d,随后4周治疗后随访。
  • 主要终点为治疗结束时(T4)咳嗽缓解率,即总咳嗽症状评分较基线下降至少50%的受试者比例。

主要发现

  • 治疗结束时加巴喷丁组咳嗽缓解率73.5%,安慰剂组26.5%,安慰剂校正绝对差47.1个百分点(95%CI 26.1-68.0,P<.001)。
  • 治疗期间加巴喷丁组不良事件发生率32.4%,安慰剂组8.8%。
  • 加巴喷丁组最常见不良事件为嗜睡、乏力、头晕。

关键数值与推荐

  • 纳入标准:根据ATS、ERS、JRS和ALAT指南诊断为IPF,慢性咳嗽持续>8周,咳嗽视觉模拟量表评分≥40 mm。
  • 主要终点咳嗽缓解定义为总咳嗽症状评分较基线下降至少50%。

临床怎么用

  • 对于IPF相关慢性咳嗽患者,可考虑试用加巴喷丁,需监测嗜睡、乏力、头晕等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cough is common in idiopathic pulmonary fibrosis (IPF) and substantially impairs quality of life, but effective treatment options are limited. Gabapentin reduces cough in refractory chronic cough, but its efficacy and safety in IPF-related cough are uncertain. RESEARCH QUESTION: Does gabapentin improve cough in patients with IPF? STUDY DESIGN AND METHODS: This study was a randomized, double-masked, placebo-controlled clinical trial conducted at Tongji Hospital, Tongji University. Patients with a diagnosis of IPF according to the American Thoracic Society, the European Respiratory Society, the JRS, and ALAT guidelines, with chronic cough lasting for > 8 weeks and a cough visual analog scale score of ≥40 mm were included. Participants were assigned randomly in a 1:1 ratio to receive either gabapentin or placebo. Gabapentin was titrated to a maximum of 900 mg/d during 12 weeks of treatment, followed by a 4-week posttreatment follow-up. The primary end point was the cough relief rate at the end of treatment (T4), defined as the proportion of participants achieving a reduction of at least 50% in total Cough Symptom Score from baseline. Safety was assessed in all participants who received at least 1 dose of study treatment. RESULTS: Between May 1, 2021, and December 31, 2024, 72 participants were screened, of whom 68 were randomized to gabapentin or placebo. Five participants withdrew before study completion. At T4, the cough relief rate was higher with gabapentin than with placebo (73.5% vs 26.5%), with a placebo-adjusted absolute difference of 47.1 percentage points (95% CI, 26.1-68.0; P < .001). During treatment, adverse events (AEs) occurred in 32.4% of participants receiving gabapentin and in 8.8% of participants receiving placebo. The most common AEs in the gabapentin group were drowsiness, fatigue, and dizziness. INTERPRETATION: Our results show that gabapentin demonstrated significant efficacy with an acceptable safety profile in treating cough in IPF. These findings support gabapentin as a potential treatment option for IPF-related cough. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry; No.: ChiCTR2100045202; URL: www.chictr.org.cn/indexEN.html.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Ju X, Zhang Y, et al. Efficacy and Safety of Gabapentin for Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized, Double-Masked, Placebo-Controlled Clinical Trial. Chest. 2026. PMID: 42668062. doi:10.1016/j.chest.2026.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。